Charvet G.,CEA Grenoble |
Billoint O.,CEA Grenoble |
Gharbi S.,CEA Grenoble |
Heuschkel M.,Ayanda Biosystems SA |
And 5 more authors.
2010 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBC'10 | Year: 2010
In order to understand the dynamics of large neural networks, where information is widely distributed over thousands of cells, one of today's challenges is to successfully monitor the simultaneous activity of as many neurons as possible. This is made possible by using the Micro-Electrode Array (MEA) technology allowing neural cell culture and/or tissue slice experimentation in vitro. Thanks to development of microelectronics' technologies, a novel data acquisition system based on MEA technology has been developed, the BioMEA™. It combines the most advanced MEA biochips with integrated electronics, and a novel user-friendly software interface. To move from prototype (result of the RMNT research project NEUROCOM) to manufactured product, a number of changes have been made. Here, we present a 256-channel MEA data acquisition system with integrated electronics (BioMEA™) allowing simultaneous recording and stimulation of neural networks for in vitro and in vivo applications. This integration is a first step towards an implantable device for BCI (Brain Computer Interface) studies and neural prosthesis. © 2010 IEEE.
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.89M | Year: 2009
The project PharMEA is based on the technology platform of multi-electrode arrays, which have been widely used for electrophysiological experiments on neuronal and cardiac tissues. Some of the key advantages of MEA technology include ease of use, non-invasive measurements and simultaneous multi-site recording & stimulation capability. Despite these key advantages, MEA technology utilization has remained largely confined in academic research institutions, primarily due to the low throughput of currently available MEA-based tools. The PharMEA project addresses these shortcomings by developing novel MEA tools and applications that will significantly increase throughput of MEA experiments, facilitate MEA experiments on various culture models, as well as associated applications tailored for the drug discovery industry. Specifically, the new MEA tools will increase the number of channels or measurement sites for simultaneous recording and stimulation from about 120 channels today to 1024 channels, along with the corresponding intelligent data handling and processing strategies. Furthermore, the PharMEA project will develop and automate biological assay protocols that are common in ion-channel based drug discovery activities, as we this will add significant value to and bring out the benefit of the proposed tools. Altogether, the results of this project will accelerate the uptake of MEA tools in the drug discovery industry, thereby significantly increasing the market opportunity and competitive edge of the various sponsoring SMEs in the lucrative drug discovery industry.
Ayanda Biosystems Sa | Date: 2011-09-23
The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.